Hepatocellular carcinoma (HCC) remains one of the leading causes of death among many associated liver diseases. Various conventional strategies have been utilized for treatment, ranging from invasive surgeries and liver transplants to radiation therapy, but fail due to advanced disease progression, late screening/staging, and the various etiologies of HCC. This is especially evident within racially distinct populations, where incidence rates are higher and treatment outcomes are worse for racial/ethnic minorities than their Caucasian counterparts. However, with the rapid development of genetic engineering and molecular and synthetic biology, many novel strategies have presented promising results and have provided potential treatment options. In this review, we summarize past treatments, how they have shaped current treatments, and potential treatment strategies for HCC that may prove more effective in the future.
肝细胞癌（HCC）仍是众多肝脏相关疾病中的主要致死原因之一。目前临床采用的传统治疗策略包括侵入性手术、肝移植及放射治疗等多种方式，但这些方法常因疾病进展至晚期、筛查/分期滞后以及肝细胞癌复杂的病因学而疗效有限。这一现象在种族差异群体中尤为显著，少数族裔的发病率更高且治疗效果较白种人群更差。然而，随着基因工程、分子生物学及合成生物学的快速发展，诸多创新性治疗策略已展现出令人鼓舞的成果，并为肝细胞癌提供了潜在的治疗选择。本文综述了既往治疗方法的发展脉络，探讨了其对当前治疗体系的影响，并展望了未来可能更有效的肝细胞癌治疗策略。
肿瘤(癌症)患者之家